Our latest articles
A highly respectable response rate with the company’s oncolytic virus bodes well in the post-checkpoint inhibitor setting.
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.
The sequencing giant’s acquisition of Grail is heading for the rocks.
Early data are promising, but the upcoming phase 2 trial has questions to answer.
With an effective obesity drug already available and more in the pipeline, what hope do devices have?
In targeting a genetic cause of the disease, Lexeo reckons it could outdo anti-amyloid antibodies, but has a long way to go.
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.